Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q3 FY2017 Earnings Presentation
13 slides from Alkem Laboratories's earnings presentation, Feb 10, 2017
Slide 1: Alkem Laboratories Ltd. Investor Presentation Q3FY17
Alkem Laboratories Ltd. Investor Presentation Q3FY17 10th February 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Financial Highlights of Q3FY17 (Consolidated)
Key Financial Highlights of Q3FY17 (Consolidated) All figures in INR mn Total Revenue from Operations India sales 10,298 9,074 14,819 12,878 Q3FY16 Q3FY17 International sales 4,324 3,644 Q3FY16 Q3FY17 Q3FY16 Q3FY17 Healthy growth in key markets of India and US amidst tough business environment
Slide 4: Key Financial Highlights of Q3FY17 (Consolidated)
Key Financial Highlights of Q3FY17 (Consolidated) All figures in INR mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 9,414 2,681 7,784 2,357 60.4% 63.5% 18.3% 18.1% Q3FY16 Q3FY17 Q3FY16 Q3FY17 PBT (before Minority Interest) PAT (after Minority Interest) 2,334 2,554 2,128 1,869 Q3FY16 Q3FY1
Slide 5: Key Financial Highlights – 9MFY17 (Consolidated)
Key Financial Highlights – 9MFY17 (Consolidated) Particulars (INR mn) 9MFY17 9MFY16 YoY growth Income from Operations 46,011 38,994 18.0% Gross Profit 28,404 23,661 20.0% Gross Profit margin 61.7% 60.7% EBITDA 8,497 6,974 21.8% EBITDA margin 18.5% 17.9% PBT 8,286 7,032 17.8% PBT margin 18.0% 18.0% P
Slide 6: India Business – Continued Outperformance
India Business – Continued Outperformance India Business: Q3FY17 Sales of Rs.10,298 million (13.5% growth YoY) • India sales contributed 70.4% to total sales for Q3FY17 • During the quarter, Company’s secondary sales1 grew by 6.2% – higher than corresponding IPM growth of 5.7% • This outperformance
Slide 7: Established Therapies – Maintain our leading positions
Established Therapies – Maintain our leading positions • During the quarter, the Company delivered more than 350bps of outperformance to the market in its established therapy areas of Anti-Infectives, Gastro-Intestinal and Pain / Analgesic • During the quarter, the Indian anti-infective market regis
Slide 8: Emerging Therapies – Building on the Base
Emerging Therapies – Building on the Base • Emerging therapies of the Company registered a healthy performance led by strong secondary sales growth in Anti- diabetic, Neuro / CNS, Cardiac and Derma • Company moved up the ranking in the important therapy areas of Anti-diabetic, Neuro / CNS and Cardia
Slide 9: US Business – Healthy growth largely led by market share gains
US Business – Healthy growth largely led by market share gains US Business: Q3FY17 Sales of Rs.3,385 million (30.1% growth YoY) • US sales contributed 23.1% to total sales for Q3FY17 • Good winter season helped the QoQ growth during the quarter • The Company launched 1 new products during the quarte
Slide 10: Other International Markets – Focusing on select markets
Other International Markets – Focusing on select markets Other International Markets : Q3FY17 Sales of Rs.939 million (9.8% de-growth YoY) • Other International sales contributed 6.4% to total sales for Q3FY17 • During 9MFY17, Company’s key markets of Australia, Chile and Kazakhstan recorded healthy
Slide 11: Strategy going forward
Strategy going forward 1 India Sales: Consolidate our leadership position in the acute segment by driving growth in our mega brands 2 India Sales: Increase our market share in the chronic segment through market share acquisition and new product introductions 3 Improve our field force productivity th
Slide 12: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on 31th December 2016 Non-Institution, 26.19% Promoter & Institution, Promoter Group, 6.83% 66.97% Institution – Mutual Funds, Financial Institutions, Foreign Portfolio Investors, Foreign Institutional Investors, Nationalised and Non-Nationalised B
Slide 13: Thank You
Thank You Contact Gagan Borana Investor Relations Tel: +91 22 39829960 / +91 98190 56333 Email: gagan.borana@alkem.com